Gilead Sciences Inc. (GILD): Price and Financial Metrics

Gilead Sciences Inc. (GILD): $77.09

-0.56 (-0.72%)

POWR Rating

Component Grades













Add GILD to Watchlist
Sign Up

Industry: Biotech



in industry

GILD Price/Volume Stats

Current price $77.09 52-week high $89.74
Prev. close $77.65 52-week low $57.17
Day low $77.01 Volume 5,439,000
Day high $78.62 Avg. volume 5,829,345
50-day MA $80.90 Dividend yield 3.86%
200-day MA $78.01 Market Cap 96.16B

GILD Stock Price Chart Interactive Chart >


  • GILD scores best on the Value dimension, with a Value rank ahead of 97.46% of US stocks.
  • The strongest trend for GILD is in Sentiment, which has been heading down over the past 179 days.
  • GILD ranks lowest in Momentum; there it ranks in the 26th percentile.

GILD Stock Summary

  • GILEAD SCIENCES INC's market capitalization of $98,603,230,065 is ahead of 97.88% of US-listed equities.
  • With a one year PEG ratio of 88.54, GILEAD SCIENCES INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 76.01% of US stocks.
  • GILD's went public 31.36 years ago, making it older than 84.55% of listed US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to GILEAD SCIENCES INC, a group of peers worth examining would be ADI, GSK, AMGN, BA, and ATVI.
  • GILD's SEC filings can be seen here. And to visit GILEAD SCIENCES INC's official web site, go to

GILD Valuation Summary

  • GILD's price/earnings ratio is 17.6; this is 26.97% lower than that of the median Healthcare stock.
  • Over the past 243 months, GILD's EV/EBIT ratio has gone up 45.4.

Below are key valuation metrics over time for GILD.

Stock Date P/S P/B P/E EV/EBIT
GILD 2023-05-23 3.6 4.7 17.6 14.4
GILD 2023-05-22 3.6 4.7 17.6 14.4
GILD 2023-05-19 3.6 4.7 17.6 14.4
GILD 2023-05-18 3.6 4.6 17.5 14.3
GILD 2023-05-17 3.6 4.7 17.6 14.4
GILD 2023-05-16 3.6 4.7 17.5 14.3

GILD Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -60.73%.
  • Its 5 year net cashflow from operations growth rate is now at -41.74%.
  • The 5 year net income to common stockholders growth rate now stands at -60.73%.
Over the past 34 months, GILD's revenue has gone up $4,565,000,000.

The table below shows GILD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 27,281 9,072 4,592
2022-09-30 27,136 9,710 3,334
2022-06-30 27,515 10,100 4,137
2022-03-31 27,472 10,614 4,515
2021-12-31 27,305 11,384 6,225
2021-09-30 27,482 10,095 7,394

GILD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GILD has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
  • GILD's asset turnover comes in at 0.406 -- ranking 114th of 682 Pharmaceutical Products stocks.
  • ENTA, RDUS, and ADMS are the stocks whose asset turnover ratios are most correlated with GILD.

The table below shows GILD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.406 0.805 0.259
2021-06-30 0.402 0.801 0.179
2021-03-31 0.405 0.806 0.066
2020-12-31 0.403 0.815 0.058
2020-09-30 0.389 0.790 0.058
2020-06-30 0.375 0.786 0.009

GILD Price Target

For more insight on analysts targets of GILD, see our GILD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.84 Average Broker Recommendation 1.7 (Moderate Buy)

Gilead Sciences Inc. (GILD) Company Bio

Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. Daniel O’Day has been Gilead Science’s Chief Executive Officer since March of 2019 and the company is headquartered in Foster City, California. With over 10,000 employees worldwide, the company has operations in North America, Asia, the Middle East and Europe. As of 2019, the company had global sales of $22.1 billion. Some of Gilead Science’s major competitors are Novo Nordisk A/S ADR (NVO), Biogen Inc. (BIIB), and Novartis AG ADR (NVS).

GILD Latest News Stream

Event/Time News Detail
Loading, please wait...

GILD Latest Social Stream

Loading social stream, please wait...

View Full GILD Social Stream

Latest GILD News From Around the Web

Below are the latest news stories about GILEAD SCIENCES INC that investors may wish to consider to help them evaluate GILD as an investment opportunity.

How To Trade Stocks: Do You Know The Seven Most Important Words On Wall Street?

Want to learn how to trade stocks successfully? First examine fundamentals. And keep these seven key words on Wall Street in mind.

Yahoo | May 22, 2023

Gilead Sciences, Inc. (NASDAQ:GILD) is favoured by institutional owners who hold 85% of the company

Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...

Yahoo | May 21, 2023

3 Relatively Safe Stocks to Buy if a Recession Is on the Way

Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.

Yahoo | May 20, 2023

3 Analyst Upgrades That Smart Investors Won’t Ignore

Even the most experienced investors have only so many hours in the day to perform their due diligence.

Chris Markoch on InvestorPlace | May 17, 2023

Former Immunomedics CFO pleads guilty to insider trading

The former chief financial officer of a New Jersey biotechnology company pleaded guilty on Wednesday to insider trading, after prosecutors said he had given nonpublic information about a new breast cancer drug to his girlfriend at the time. Usama Malik, 48, former CFO of Immunomedics Inc, now owned by Gilead Sciences Inc, admitted to a single charge of securities fraud at a hearing before U.S. District Judge John Michael Vazquez in Newark, New Jersey.

Yahoo | May 17, 2023

Read More 'GILD' Stories Here

GILD Price Returns

1-mo -6.23%
3-mo -3.36%
6-mo -10.66%
1-year 24.00%
3-year 12.40%
5-year 38.77%
YTD -9.35%
2022 23.63%
2021 29.95%
2020 -6.70%
2019 7.88%
2018 -9.92%

GILD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GILD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8247 seconds.